South San Francisco, CA
Second Genome To Present Biomarker Data in Oncology at Keystone Symposium
January 19, 2021, South San Francisco, CA
Second Genome To Present at Biotech Showcase Digital 2021 Conference
January 11, 2021, South San Francisco, CA
Second Genome Expands Development of CNS Platform to Validate Microbial Products as Therapeutics for Autism Spectrum Disorder
March 26, 2019, South San Francisco, CA
Second Genome Doses First Patient In Phase 2 Clinical Study Of SGM-1019 For The Treatment Of Nonalcoholic Steatohepatitis (NASH)
January 23, 2019, South San Francisco, CA
Second Genome Appoints Karim Dabbagh, Ph.D., as Chief Executive Officer
September 26, 2018, South San Francisco, CA
Second Genome Appoints Anupama S. Hoey as Chief Business Officer
July 23, 2018, South San Francisco, CA
Second Genome Presents Clinical and Preclinical Data Supporting Development of Its P2X7 Inhibitor, SGM-1019, in NASH at the EASL International Liver Congress 2018
April 9, 2018, South San Francisco, CA